Collaborators GBDDF . Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 . Lancet Public Health . 2022 ; 7 ( 2 ): e105 - e25 .

Kurtishi A , Rosen B , Patil KS , Alves GW , Møller SG . Cellular proteostasis in neurodegeneration . Mol Neurobiol . 2019 ; 56 ( 5 ): 3676 - 89 .

Katsnelson A , De Strooper B , Zoghbi HY . Neurodegeneration: from cellular concepts to clinical applications . Sci Transl Med . 2016 ; 8 ( 364 ): 364ps18 .

Davis AA , Leyns CEG , Holtzman DM . Intercellular spread of protein aggregates in neurodegenerative disease . Annu Rev Cell Dev Biol . 2018 ; 34 : 545 - 68 .

Sun J , Roy S . Gene-based therapies for neurodegenerative diseases . Nat Neurosci . 2021 ; 24 ( 3 ): 297 - 311 .

Sengupta U , Kayed R . Amyloid beta, tau, and alpha-synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases . Prog Neurobiol . 2022 ; 214 : 102270 .

Temple S . Advancing cell therapy for neurodegenerative diseases . Cell Stem Cell . 2023 ; 30 ( 5 ): 512 - 29 .

Palanisamy CP , Pei J , Alugoju P , Anthikapalli NVA , Jayaraman S , Veeraraghavan VP , et al . New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) . Theranostics . 2023 ; 13 ( 12 ): 4138 - 65 .

Armstrong R . What causes neurodegenerative disease? . Folia Neuropathol . 2020 ; 58 ( 2 ): 93 - 112 .

Mckinnon C , Tabrizi SJ . The ubiquitin-proteasome system in neurodegeneration . Antioxid Redox Signal . 2014 ; 21 ( 17 ): 2302 - 21 .

Huang Q , Figueiredo-Pereira ME . Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications . Apoptosis . 2010 ; 15 ( 11 ): 1292 - 311 .

Ricci C . Neurodegenerative disease: from molecular basis to therapy . Int J Mol Sci . 2024 ; 25 ( 2 ): 967 .

Lee J , Lee Y , Jung YM , Park JH , Yoo HS , Park J . Discovery of E3 ligase ligands for target protein degradation . Molecules . 2022 ; 27 ( 19 ): 6515 .

Upadhyay A , Amanullah A , Chhangani D , Mishra R , Mishra A . Selective multifaceted E3 ubiquitin ligases barricade extreme defense: Potential therapeutic targets for neurodegeneration and ageing . Ageing Res Rev . 2015 ; 24 ( Pt B ): 138 - 59 .

Rape M . Ubiquitylation at the crossroads of development and disease . Nat Rev Mol Cell Biol . 2018 ; 19 ( 1 ): 59 - 70 .

Liu F , Chen J , Li K , Li H , Zhu Y , Zhai Y , et al . Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches . Mol Cancer . 2024 ; 23 ( 1 ): 148 .

Sun-Wang JL , Ivanova S , Zorzano A . The dialogue between the ubiquitin-proteasome system and autophagy: implications in ageing . Ageing Res Rev . 2020 ; 64 : 101203 .

Kamber Kaya HE , Radhakrishnan SK . Trash talk: mammalian proteasome regulation at the transcriptional level . Trends Genet . 2021 ; 37 ( 2 ): 160 - 73 .

Yang Q , Zhao J , Chen D , Wang Y . E3 ubiquitin ligases: styles, structures and functions . Mol Biomed . 2021 ; 2 ( 1 ): 23 .

Huang X , Chen J , Cao W , Yang L , Chen Q , He J , et al . The many substrates and functions of NEDD4-1 . Cell Death Dis . 2019 ; 10 ( 12 ): 904 .

Jahan AS , Elbæk CR , Damgaard RB . Met1-linked ubiquitin signalling in health and disease: inflammation, immunity, cancer, and beyond . Cell Death Differ . 2021 ; 28 ( 2 ): 473 - 92 .

Elia AE , Boardman AP , Wang DC , Huttlin EL , Everley RA , Dephoure N , et al . Quantitative proteomic atlas of ubiquitination and acetylation in the DNA damage response . Mol Cell . 2015 ; 59 ( 5 ): 867 - 81 .

Lee JS , Kim HY , Kwon YT , Ji CH , Lee SJ , Kim SB . The ubiquitin code in disease pathogenesis and progression: composition, characteristics and its potential as a therapeutic target . Discov Med . 2025 ; 37 ( 193 ): 203 - 21 .

Tracz M , Bialek W . Beyond K48 and K63: non-canonical protein ubiquitination . Cell Mol Biol Lett . 2021 ; 26 ( 1 ): 1 .

Kolla S , Ye M , Mark KG , Rape M . Assembly and function of branched ubiquitin chains . Trends Biochem Sci . 2022 ; 47 ( 9 ): 759 - 71 .

Madiraju C , Novack JP , Reed JC , Matsuzawa SI . K63 ubiquitination in immune signaling . Trends Immunol . 2022 ; 43 ( 2 ): 148 - 62 .

Cao L , Liu X , Zheng B , Xing C , Liu J . Role of K63-linked ubiquitination in cancer . Cell Death Discov . 2022 ; 8 ( 1 ): 410 .

Moreno SP , Gambus A . Regulation of unperturbed DNA replication by ubiquitylation . Genes (Basel) . 2015 ; 6 ( 3 ): 451 - 68 .

French ME , Koehler CF , Hunter T . Emerging functions of branched ubiquitin chains . Cell Discov . 2021 ; 7 ( 1 ): 6 .

Liao Y , Sumara I , Pangou E . Non-proteolytic ubiquitylation in cellular signaling and human disease . Commun Biol . 2022 ; 5 ( 1 ): 114 .

Ball KA , Johnson JR , Lewinski MK , Guatelli J , Verschueren E , Krogan NJ , et al . Non-degradative ubiquitination of protein kinases . PLoS Comput Biol . 2016 ; 12 ( 6 ): e1004898 .

Glorian V , Allègre J , Berthelet J , Dumetier B , Boutanquoi PM , Droin N , et al . DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues . Cell Death Dis . 2017 ; 8 ( 5 ): e2816 .

Keating SE , Bowie AG . Role of non-degradative ubiquitination in interleukin-1 and toll-like receptor signaling . J Biol Chem . 2009 ; 284 ( 13 ): 8211 - 5 .

Skrajna A , Bodrug T , Martinez-Chacin RC , Fisher CB , Welsh KA , Simmons HC , et al . APC/C-mediated ubiquitylation of extranucleosomal histone complexes lacking canonical degrons . Nat Commun . 2025 ; 16 ( 1 ): 2561 .

Tang LY , Zhang YE . Non-degradative ubiquitination in Smad-dependent TGF-β signaling . Cell Biosci . 2011 ; 1 ( 1 ): 43 .

Loix M , Zelcer N , Bogie JFJ , Hendriks JJA . The ubiquitous role of ubiquitination in lipid metabolism . Trends Cell Biol . 2024 ; 34 ( 5 ): 416 - 29 .

Pao KC , Wood NT , Knebel A , Rafie K , Stanley M , Mabbitt PD , et al . Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity . Nature . 2018 ; 556 ( 7701 ): 381 - 5 .

Koren I , Timms RT , Kula T , Xu Q , Li MZ , Elledge SJ . The eukaryotic proteome is shaped by E3 ubiquitin ligases targeting C-terminal degrons . Cell . 2018 ; 173 ( 7 ): 1622 - 35.e14 .

Ji F , Zhou M , Sun Z , Jiang Z , Zhu H , Xie Z , et al . Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis . Cancer Commun (Lond) . 2021 ; 41 ( 10 ): 1007 - 23 .

Popovic D , Vucic D , Dikic I . Ubiquitination in disease pathogenesis and treatment . Nat Med . 2014 ; 20 ( 11 ): 1242 - 53 .

Manasanch EE , Orlowski RZ . Proteasome inhibitors in cancer therapy . Nat Rev Clin Oncol . 2017 ; 14 ( 7 ): 417 - 33 .

Toma-Fukai S , Shimizu T . Structural diversity of ubiquitin E3 ligase . Molecules . 2021 ; 26 ( 21 ): 6682 .

Sherpa D , Chrustowicz J , Schulman BA . How the ends signal the end: regulation by E3 ubiquitin ligases recognizing protein termini . Mol Cell . 2022 ; 82 ( 8 ): 1424 - 38 .

Cai C , Tang YD , Zhai J , Zheng C . The RING finger protein family in health and disease . Signal Transduct Target Ther . 2022 ; 7 ( 1 ): 300 .

Lorick KL , Jensen JP , Fang S , Ong AM , Hatakeyama S , Weissman AM . RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination . Proc Natl Acad Sci U S A . 1999 ; 96 ( 20 ): 11364 - 9 .

Zheng N , Shabek N . Ubiquitin ligases: structure, function, and regulation . Annu Rev Biochem . 2017 ; 86 : 129 - 57 .

Liu N , Lin MM , Wang Y . The emerging roles of E3 ligases and DUBs in neurodegenerative diseases . Mol Neurobiol . 2023 ; 60 ( 1 ): 247 - 63 .

Bauer J , Bakke O , Morth JP . Overview of the membrane-associated RING-CH (MARCH) E3 ligase family . N Biotechnol . 2017 ; 38 ( Pt A ): 7 - 15 .

Erickson AH . PA-TM-RING proteins: a new family of endosomal membrane proteins . FEBS J . 2011 ; 278 ( 1 ): 46 .

Dudley-Fraser J , Rittinger K . It's a TRIM-endous view from the top: the varied roles of TRIpartite Motif proteins in brain development and disease . Front Mol Neurosci . 2023 ; 16 : 1287257 .

Metzger MB , Hristova VA , Weissman AM . HECT and RING finger families of E3 ubiquitin ligases at a glance . J Cell Sci . 2012 ; 125 ( Pt 3 ): 531 - 7 .

Tetzlaff JE , Putcha P , Outeiro TF , Ivanov A , Berezovska O , Hyman BT , et al . CHIP targets toxic alpha-Synuclein oligomers for degradation . J Biol Chem . 2008 ; 283 ( 26 ): 17962 - 8 .

Wang XS , Cotton TR , Trevelyan SJ , Richardson LW , Lee WT , Silke J , et al . The unifying catalytic mechanism of the RING-between-RING E3 ubiquitin ligase family . Nat Commun . 2023 ; 14 ( 1 ): 168 .

Beasley SA , Hristova VA , Shaw GS . Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson’s disease . Proc Natl Acad Sci U S A . 2007 ; 104 ( 9 ): 3095 - 100 .

Byrd RA , Weissman AM . Compact Parkin only: insights into the structure of an autoinhibited ubiquitin ligase . EMBO J . 2013 ; 32 ( 15 ): 2087 - 9 .

Trempe JF , Sauve V , Grenier K , Seirafi M , Tang MY , Menade M , et al . Structure of parkin reveals mechanisms for ubiquitin ligase activation . Science . 2013 ; 340 ( 6139 ): 1451 - 5 .

Narendra DP , Jin SM , Tanaka A , Suen DF , Gautier CA , Shen J , et al . PINK1 is selectively stabilized on impaired mitochondria to activate Parkin . PLoS Biol . 2010 ; 8 ( 1 ): e1000298 .

Miller S , Muqit MMK . Therapeutic approaches to enhance PINK1/Parkin mediated mitophagy for the treatment of Parkinson’s disease . Neurosci Lett . 2019 ; 705 : 7 - 13 .

Takeda K , Flechsig H , Muro I , Amyot R , Kobayashi F , Kodera N , et al . Structural dynamics of E6AP E3 ligase HECT domain and involvement of a flexible hinge loop in the ubiquitin chain synthesis mechanism . Nano Lett . 2023 ; 23 ( 24 ): 11940 - 8 .

Wang Y , Argiles-Castillo D , Kane EI , Zhou A , Spratt DE . HECT E3 ubiquitin ligases-emerging insights into their biological roles and disease relevance . J Cell Sci . 2020 ; 133 ( 7 ): jcs228072 .

Ozansoy M , Başak AN . The central theme of Parkinson’s disease: α-synuclein . Mol Neurobiol . 2013 ; 47 ( 2 ): 460 - 5 .

Lang F , Pelzl L , Hauser S , Hermann A , Stournaras C , Schols L . To die or not to die SGK1-sensitive ORAI/STIM in cell survival . Cell Calcium . 2018 ; 74 : 29 - 34 .

Yin Q , Wyatt CJ , Han T , Smalley KSM , Wan L . ITCH as a potential therapeutic target in human cancers . Semin Cancer Biol . 2020 ; 67 ( Pt 2 ): 117 - 30 .

Haouari S , Andres CR , Lanznaster D , Marouillat S , Brulard C , Dangoumau A , et al . Study of ubiquitin pathway genes in a french population with amyotrophic lateral sclerosis: focus on HECW1 encoding the E3 ligase NEDL1 . Int J Mol Sci . 2023 ; 24 ( 2 ).

Chen H , Gong Y , Wu F , Wu M , Li S , Chen B , et al . WWP1-SHARP1-C/EBPβ positive feedback loop modulates development of metabolic dysfunction-associated steatotic liver disease . Metabolism . 2025 ; 169 : 156271 .

Sanchez-Tena S , Cubillos-Rojas M , Schneider T , Rosa JL . Functional and pathological relevance of HERC family proteins: a decade later . Cell Mol Life Sci . 2016 ; 73 ( 10 ): 1955 - 68 .

Nakamura M , Ito H , Nakamura Y , Wate R , Kaneko S , Nakano S , et al . Smad ubiquitination regulatory factor-2 in progressive supranuclear palsy . Neuropathol Appl Neurobiol . 2011 ; 37 ( 3 ): 307 - 14 .

Haouari S , Vourc'h P , Jeanne M , Marouillat S , Veyrat-Durebex C , Lanznaster D , et al . The roles of NEDD4 subfamily of HECT E3 ubiquitin ligases in neurodevelopment and neurodegeneration . Int J Mol Sci . 2022 ; 23 ( 7 ): 1268 .

Harlalka GV , Baple EL , Cross H , Kuhnle S , Cubillos-Rojas M , Matentzoglu K , et al . Mutation of HERC2 causes developmental delay with Angelman-like features . J Med Genet . 2013 ; 50 ( 2 ): 65 - 73 .

Mishra A , Dikshit P , Purkayastha S , Sharma J , Nukina N , Jana NR . E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity . J Biol Chem . 2008 ; 283 ( 12 ): 7648 - 56 .

Owais A , Mishra RK , Kiyokawa H . The HECT E3 ligase E6AP/UBE3A as a therapeutic target in cancer and neurological disorders . Cancers (Basel) . 2020 ; 12 ( 8 ): 2108 .

Xia Q , Liu X , Zhong L , Qu J , Dong L . SMURF1 mediates damaged lysosomal homeostasis by ubiquitinating PPP3CB to promote the activation of TFEB . Autophagy . 2025 ; 21 ( 3 ): 530 - 47 .

Huang HS , Allen JA , Mabb AM , King IF , Miriyala J , Taylor-Blake B , et al . Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons . Nature . 2011 ; 481 ( 7380 ): 185 - 9 .

Kouli A , Torsney KM , Kuan WL . Parkinson’s disease: etiology, neuropathology, and pathogenesis . In: Stoker TB , Greenland JC , eds. Parkinson’s disease: pathogenesis and clinical aspects . Brisbane (AU) ; 2018 .

Soto C , Pritzkow S . Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases . Nat Neurosci . 2018 ; 21 ( 10 ): 1332 - 40 .

Krismer F , Fanciulli A , Meissner WG , Coon EA , Wenning GK . Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment . Lancet Neurol . 2024 ; 23 ( 12 ): 1252 - 66 .

Zheng H , Sun H , Cai Q , Tai HC . The enigma of tau protein aggregation: mechanistic insights and future challenges . Int J Mol Sci . 2024 ; 25 ( 9 ): 4969 .

Zhang H , Wei W , Zhao M , Ma L , Jiang X , Pei H , et al . Interaction between Aβ and tau in the pathogenesis of Alzheimer’s disease . Int J Biol Sci . 2021 ; 17 ( 9 ): 2181 - 92 .

Lin L , Jin Z , Tan H , Xu Q , Peng T , Li H . Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin . Brain Res . 2016 ; 1643 : 103 - 12 .

Dong L , Liu L , Li Y , Li W , Zhou L , Xia Q . E3 ligase Smurf1 protects against misfolded SOD1 in neuronal cells by promoting its K63 ubiquitylation and aggresome formation . Hum Mol Genet . 2022 ; 31 ( 12 ): 2035 - 48 .

Chaudhary R , Agarwal V , Rehman M , Kaushik AS , Mishra V . Genetic architecture of motor neuron diseases . J Neurol Sci . 2022 ; 434 : 120099 .

Devi L , Raghavendran V , Prabhu BM , Avadhani NG , Anandatheerthavarada HK . Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain . J Biol Chem . 2008 ; 283 ( 14 ): 9089 - 100 .

Bharadwaj PR , Dubey AK , Masters CL , Martins RN , Macreadie IG . Abeta aggregation and possible implications in Alzheimer’s disease pathogenesis . J Cell Mol Med . 2009 ; 13 ( 3 ): 412 - 21 .

Clausen L , Okarmus J , Voutsinos V , Meyer M , Lindorff-Larsen K , Hartmann-Petersen R . PRKN-linked familial Parkinson’s disease: cellular and molecular mechanisms of disease-linked variants . Cell Mol Life Sci . 2024 ; 81 ( 1 ): 223 .

Verde EM , Secco V , Ghezzi A , Mandrioli J , Carra S . Molecular mechanisms of protein aggregation in ALS-FTD: focus on TDP-43 and cellular protective responses . Cells . 2025 ; 14 ( 10 ): 680 .

Brudek T , Winge K , Rasmussen NB , Bahl JM , Tanassi J , Agander TK , et al . Altered alpha-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains . J Neurochem . 2016 ; 136 ( 1 ): 172 - 85 .

Urushitani M , Kurisu J , Tateno M , Hatakeyama S , Nakayama K , Kato S , et al . CHIP promotes proteasomal degradation of familial ALS-linked mutant SOD1 by ubiquitinating Hsp/Hsc70 . J Neurochem . 2004 ; 90 ( 1 ): 231 - 44 .

Ge P , Dawson VL , Dawson TM . PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease . Mol Neurodegener . 2020 ; 15 ( 1 ): 20 .

Dawson TM , Dawson VL . The role of parkin in familial and sporadic Parkinson’s disease . Mov Disord . 2010 ; 25 Suppl 1 ( 01 ): S32 - 9 .

Chung KK , Thomas B , Li X , Pletnikova O , Troncoso JC , Marsh L , et al . S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function . Science . 2004 ; 304 ( 5675 ): 1328 - 31 .

Schmidt SI , Okarmus J , Madsen DA , Hansen JS , Gregersen E , Gram H , et al . Formation of seeding-competent alpha-synuclein aggregates in parkin-deficient iPSC-derived human neurons . NPJ Parkinsons Dis . 2025 ; 11 ( 1 ): 180 .

Madsen DA , Schmidt SI , Blaabjerg M , Meyer M . Interaction between Parkin and alpha-synuclein in PARK2-mediated Parkinson’s disease . Cells . 2021 ; 10 ( 2 ): 283 .

Khandelwal PJ , Dumanis SB , Feng LR , Maguire-Zeiss K , Rebeck G , Lashuel HA , et al . Parkinson-related parkin reduces alpha-synuclein phosphorylation in a gene transfer model . Mol Neurodegener . 2010 ; 5 : 47 .

Shimura H , Schlossmacher MG , Hattori N , Frosch MP , Trockenbacher A , Schneider R , et al . Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease . Science . 2001 ; 293 ( 5528 ): 263 - 9 .

Chung KK , Zhang Y , Lim KL , Tanaka Y , Huang H , Gao J , et al . Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease . Nat Med . 2001 ; 7 ( 10 ): 1144 - 50 .

Xu D , Shentu C , Zong C , Fu W , Ling J , Shao P , et al . Proteomics based discovery of Salvia miltiorrhiza Bunge treating Parkinson’s disease through the PINK1/Parkin pathway . J Ethnopharmacol . 2025 ; 350 : 120079 .

Ye H , Li D , Zhang L , Wang Y , Wang C , Jin M , et al . Epicoccin A ameliorates PD-like symptoms in zebrafish: enhancement of PINK1/Parkin-dependent mitophagy and inhibition of excessive oxidative stress . Mar Drugs . 2025 ; 23 ( 4 ): 175 .

Moussa CE . Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein . J Mol Neurosci . 2009 ; 37 ( 1 ): 25 - 36 .

Qi Y , Zhang J , Zhang Y , Zhu H , Wang J , Xu X , et al . Curcuma wenyujin extract alleviates cognitive deficits and restrains pyroptosis through PINK1/Parkin mediated autophagy in Alzheimer’s disease . Phytomedicine . 2025 ; 139 : 156482 .

Han Y , Wang N , Kang J , Fang Y . beta-Asarone improves learning and memory in Abeta(1-42)-induced Alzheimer’s disease rats by regulating PINK1-Parkin-mediated mitophagy . Metab Brain Dis . 2020 ; 35 ( 7 ): 1109 - 17 .

Gao Y , Li J , Li J , Hu C , Zhang L , Yan J , et al . Tetrahydroxy stilbene glycoside alleviated inflammatory damage by mitophagy via AMPK related PINK1/Parkin signaling pathway . Biochem Pharmacol . 2020 ; 177 : 113997 .

Luo R , Kang Y , Ma H , Zhang Z , Holscher C , Hao L , et al . A novel dual CCK/ GLP-1 receptor agonist ameliorates cognitive impairment in 5×FAD mice by modulating mitophagy via the PINK1/Parkin pathway . Int Immunopharmacol . 2025 ; 154 : 114612 .

Noda S , Sato S , Fukuda T , Ueno S , Tada N , Hattori N . Impaired mitochondrial accumulation and Lewy pathology in neuron-specific FBXO7-deficient mice . Mol Brain . 2022 ; 15 ( 1 ): 54 .

Zhou ZD , Xie SP , Sathiyamoorthy S , Saw WT , Sing TY , Ng SH , et al . F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy . Hum Mol Genet . 2015 ; 24 ( 22 ): 6314 - 30 .

Chen L , Brewer MD , Guo L , Wang R , Jiang P , Yang X . Enhanced degradation of misfolded proteins promotes tumorigenesis . Cell Rep . 2017 ; 18 ( 13 ): 3143 - 54 .

Jena KK , Kolapalli SP , Mehto S , Nath P , Das B , Sahoo PK , et al . TRIM16 controls assembly and degradation of protein aggregates by modulating the p62-NRF2 axis and autophagy . EMBO J . 2018 ; 37 ( 18 ): e98358 .

Lassot I , Mora S , Lesage S , Zieba BA , Coque E , Condroyer C , et al . The E3 ubiquitin ligases TRIM17 and TRIM41 modulate α-synuclein expression by regulating ZSCAN21 . Cell Rep . 2018 ; 25 ( 9 ): 2484 - 96.e9 .

Rousseaux MW , De Haro M , Lasagna-Reeves CA , De Maio A , Park J , Jafar-Nejad P , et al . TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau . Elife . 2016 ; 5 .

Rousseaux MW , Revelli JP , Vázquez-Vélez GE , Kim JY , Craigen E , Gonzales K , et al . Depleting Trim28 in adult mice is well tolerated and reduces levels of α-synuclein and tau . Elife . 2018 ; 7 .

Zhu G , Harischandra DS , Ghaisas S , Zhang P , Prall W , Huang L , et al . TRIM11 prevents and reverses protein aggregation and rescues a mouse model of Parkinson’s disease . Cell Rep . 2020 ; 33 ( 9 ): 108418 .

Zhao Z , Song X , Wang Y , Yu L , Huang G , Li Y , et al . E3 ubiquitin ligase TRIM31 alleviates dopaminergic neurodegeneration by promoting proteasomal degradation of VDAC1 in Parkinson’s disease model . Cell Death Differ . 2024 ; 31 ( 11 ): 1410 - 21 .

Liu B , Zhang M , Chu H , Zhang H , Wu H , Song G , et al . The ubiquitin E3 ligase TRIM31 promotes aggregation and activation of the signaling adaptor MAVS through Lys63-linked polyubiquitination . Nat Immunol . 2017 ; 18 ( 2 ): 214 - 24 .

Zhang J , Cao L , Wang X , Li Q , Zhang M , Cheng C , et al . The E3 ubiquitin ligase TRIM31 plays a critical role in hypertensive nephropathy by promoting proteasomal degradation of MAP3K7 in the TGF-beta1 signaling pathway . Cell Death Differ . 2022 ; 29 ( 3 ): 556 - 67 .

Lizama BN , Palubinsky AM , Mclaughlin B . Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues . Neurochem Int . 2018 ; 117 : 139 - 55 .

Shin Y , Klucken J , Patterson C , Hyman BT , Mclean PJ . The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways . J Biol Chem . 2005 ; 280 ( 25 ): 23727 - 34 .

Ko HS , Bailey R , Smith WW , Liu Z , Shin JH , Lee YI , et al . CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity . Proc Natl Acad Sci U S A . 2009 ; 106 ( 8 ): 2897 - 902 .

Chen J , Xue J , Ruan J , Zhao J , Tang B , Duan R . Drosophila CHIP protects against mitochondrial dysfunction by acting downstream of Pink1 in parallel with Parkin . FASEB j . 2017 ; 31 ( 12 ): 5234 - 45 .

Zimprich A , Biskup S , Leitner P , Lichtner P , Farrer M , Lincoln S , et al . Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology . Neuron . 2004 ; 44 ( 4 ): 601 - 7 .

Saidi LJ , Polydoro M , Kay KR , Sanchez L , Mandelkow EM , Hyman BT , et al . Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes . J Alzheimers Dis . 2015 ; 44 ( 3 ): 937 - 47 .

Del Prete D , Rice RC , Rajadhyaksha AM , D'adamio L . Amyloid precursor protein (APP) may act as a substrate and a recognition unit for CRL4CRBN and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration . J Biol Chem . 2016 ; 291 ( 33 ): 17209 - 27 .

Tang Z , Cao J , Yao J , Fan X , Zhao J , Zhao M , et al . KDM1A-mediated upregulation of METTL3 ameliorates Alzheimer’s disease via enhancing autophagic clearance of p-tau through m 6 A-dependent regulation of STUB1 . Free Radic Biol Med . 2023 ; 195 : 343 - 58 .

Nadel CM , Thwin AC , Callahan M , Lee K , Connelly E , Craik CS , et al . The E3 ubiquitin ligase, CHIP/STUB1, inhibits aggregation of phosphorylated proteoforms of microtubule-associated protein tau (MAPT) . J Mol Biol . 2023 ; 435 ( 11 ): 168026 .

Roux T , Barbier M , Papin M , Davoine CS , Sayah S , Coarelli G , et al . Clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment . Genet Med . 2020 ; 22 ( 11 ): 1851 - 62 .

Nanetti L , Magri S , Fichera M , Castaldo A , Nigri A , Pinardi C , et al . Complex ataxia-dementia phenotype in patients with digenic TBP/STUB1 spinocerebellar ataxia . Mov Disord . 2023 ; 38 ( 4 ): 665 - 75 .

Joshi V , Upadhyay A , Kumar A , Mishra A . Gp78 E3 ubiquitin ligase: essential functions and contributions in proteostasis . Front Cell Neurosci . 2017 ; 11 : 259 .

Fu M , St-Pierre P , Shankar J , Wang PT , Joshi B , Nabi IR . Regulation of mitophagy by the Gp78 E3 ubiquitin ligase . Mol Biol Cell . 2013 ; 24 ( 8 ): 1153 - 62 .

Sap KA , Geijtenbeek KW , Schipper-Krom S , Guler AT , Reits EA . Ubiquitin-modifying enzymes in Huntington’s disease . Front Mol Biosci . 2023 ; 10 : 1107323 .

Seo BA , Kim D , Hwang H , Kim MS , Ma SX , Kwon SH , et al . TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson’s disease . Neuron . 2021 ; 109 ( 23 ): 3758 - 74 e11 .

Ingersoll AJ , Mccloud DM , Hu JY , Rape M . Dynamic regulation of the oxidative stress response by the E3 ligase TRIP12 . Cell Rep . 2025 ; 44 ( 9 ): 116262 .

Gong T , Wang QD , Loughran PA , Li YH , Scott MJ , Billiar TR , et al . Mechanism of lactic acidemia-promoted pulmonary endothelial cells death in sepsis: role for CIRP-ZBP1-PANoptosis pathway . Mil Med Res . 2024 ; 11 ( 1 ): 71 .

Goyani S , Shinde A , Shukla S , Saranga MV , Currim F , Mane M , et al . Enhanced translocation of TRIM32 to mitochondria sensitizes dopaminergic neuronal cells to apoptosis during stress conditions in Parkinson’s disease . FEBS J . 2024 ; 291 ( 12 ): 2636 - 55 .

Gonzalez-Cano L , Menzl I , Tisserand J , Nicklas S , Schwamborn JC . Parkinson’s disease- associated mutant LRRK2-mediated inhibition of miRNA activity is antagonized by TRIM32 . Mol Neurobiol . 2018 ; 55 ( 4 ): 3490 - 8 .

Pavlou MaS , Colombo N , Fuertes-Alvarez S , Nicklas S , Cano LG , Marín MC , et al . Expression of the Parkinson’s disease-associated gene alpha-synuclein is regulated by the neuronal cell fate determinant TRIM32 . Mol Neurobiol . 2017 ; 54 ( 6 ): 4257 - 70 .

Mukadam AS , Miller LVC , Smith AE , Vaysburd M , Sakya SA , Sanford S , et al . Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models . Science . 2023 ; 379 ( 6639 ): 1336 - 41 .

Gomez-Tortosa E , Baradaran-Heravi Y , Dillen L , Choudhury NR , Aguero Rabes P , Perez-Perez J , et al . TRIM25 mutation (p.C168*), coding for an E3 ubiquitin ligase, is a cause of early-onset autosomal dominant dementia with amyloid load and parkinsonism . Alzheimers Dement . 2023 ; 19 ( 7 ): 2805 - 15 .

Gong B , Chen F , Pan Y , Arrieta-Cruz I , Yoshida Y , Haroutunian V , et al . SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer’s disease amyloidosis and improves synaptic function . Aging Cell . 2010 ; 9 ( 6 ): 1018 - 31 .

Atkin G , Hunt J , Minakawa E , Sharkey L , Tipper N , Tennant W , et al . F-box only protein 2 (Fbxo2) regulates amyloid precursor protein levels and processing . J Biol Chem . 2014 ; 289 ( 10 ): 7038 - 48 .

Shi CS , Kehrl JH . TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy . Sci Signal . 2010 ; 3 ( 123 ): ra42 .

Akama KT , Van Eldik LJ . Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β- and tumor necrosis factor-α (TNF-α)-dependent, and involves a TNF-α receptor-associated factor- and NF-κB-inducing kinase-dependent signaling mechanism . J Biol Chem . 2000 ; 275 ( 11 ): 7918 - 24 .

Takeda K , Uda A , Mitsubori M , Nagashima S , Iwasaki H , Ito N , et al . Mitochondrial ubiquitin ligase alleviates Alzheimer’s disease pathology via blocking the toxic amyloid-beta oligomer generation . Commun Biol . 2021 ; 4 ( 1 ): 192 .

Morozko EL , Smith-Geater C , Monteys AM , Pradhan S , Lim RG , Langfelder P , et al . PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington’s disease . Proc Natl Acad Sci U S A . 2021 ; 118 ( 4 ): e2021836118 .

Lee YH , Tsai YS , Chang CC , Ho CC , Shih HM , Chen HM , et al . A PIAS1 protective variant S510G delays polyQ disease onset by modifying protein homeostasis . Mov Disord . 2022 ; 37 ( 4 ): 767 - 77 .

Ochaba J , Monteys AM , O'rourke JG , Reidling JC , Steffan JS , Davidson BL , et al . PIAS1 regulates mutant huntingtin accumulation and Huntington’s disease-associated phenotypes in vivo . Neuron . 2016 ; 90 ( 3 ): 507 - 20 .

Qin Y , Chen L , Zhu W , Song J , Lin J , Li Y , et al . TRIM37 is a primate-specific E3 ligase for Huntingtin and accounts for the striatal degeneration in Huntington’s disease . Sci Adv . 2024 ; 10 ( 20 ): eadl2036 .

Gomez-Pastor R , Burchfiel ET , Neef DW , Jaeger AM , Cabiscol E , Mckinstry SU , et al . Abnormal degradation of the neuronal stress-protective transcription factor HSF1 in Huntington’s disease . Nat Commun . 2017 ; 8 : 14405 .

Nagano Y , Yamashita H , Takahashi T , Kishida S , Nakamura T , Iseki E , et al . Siah-1 facilitates ubiquitination and degradation of synphilin-1 . J Biol Chem . 2003 ; 278 ( 51 ): 51504 - 14 .

Lee JT , Wheeler TC , Li L , Chin LS . Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death . Hum Mol Genet . 2008 ; 17 ( 6 ): 906 - 17 .

Ma P , Li Y , Wang H , Mao B . Haploinsufficiency of the TDP43 ubiquitin E3 ligase RNF220 leads to ALS-like motor neuron defects in the mouse . J Mol Cell Biol . 2021 ; 13 ( 5 ): 374 - 82 .

Van Hummel A , Sabale M , Przybyla M , Van Der Hoven J , Chan G , Feiten AF , et al . TDP-43 pathology and functional deficits in wild-type and ALS/FTD mutant cyclin F mouse models . Neuropathol Appl Neurobiol . 2023 ; 49 ( 2 ): e12902 .

Ngoi P , Wang X , Putta S , Da Luz RF , Serrão VHB , Emanuele MJ , et al . Structural mechanism for the recognition of E2F1 by the ubiquitin ligase adaptor cyclin F . Proc Natl Acad Sci U S A . 2025 ; 122 ( 26 ): e2501057122 .

Lee A , Rayner SL , Gwee SSL , De Luca A , Shahheydari H , Sundaramoorthy V , et al . Pathogenic mutation in the ALS/FTD gene, CCNF, causes elevated Lys48-linked ubiquitylation and defective autophagy . Cell Mol Life Sci . 2018 ; 75 ( 2 ): 335 - 54 .

Farrawell NE , Bax M , Mcalary L , Mckenna J , Maksour S , Do-Ha D , et al . ALS-linked CCNF variant disrupts motor neuron ubiquitin homeostasis . Hum Mol Genet . 2023 ; 32 ( 14 ): 2386 - 98 .

Davidson JM , Wu SSL , Rayner SL , Cheng F , Duncan K , Russo C , et al . The E3 ubiquitin ligase SCF cyclin F promotes sequestosome-1/p62 insolubility and foci formation and is dysregulated in ALS and FTD pathogenesis . Mol Neurobiol . 2023 ; 60 ( 9 ): 5034 - 54 .

Zhang L , Haraguchi S , Koda T , Hashimoto K , Nakagawara A . Muscle atrophy and motor neuron degeneration in human NEDL1 transgenic mice . J Biomed Biotechnol . 2011 ; 2011 : 831092 .

Pratt WB , Gestwicki JE , Osawa Y , Lieberman AP . Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases . Annu Rev Pharmacol Toxicol . 2015 ; 55 : 353 - 71 .

Gu X , Hou Y , Chen Y , Ou R , Cao B , Wei Q , et al . Enrichment of rare variants in E3 ubiquitin ligase genes in Early onset Parkinson’s disease . Neurobiol Aging . 2022 ; 109 : 273 - 8 .

Imai Y , Kobayashi Y , Inoshita T , Meng H , Arano T , Uemura K , et al . The Parkinson’s disease-associated protein kinase LRRK2 modulates notch signaling through the endosomal pathway . PLoS Genet . 2015 ; 11 ( 9 ): e1005503 .

Kühnle S , Kogel U , Glockzin S , Marquardt A , Ciechanover A , Matentzoglu K , et al . Physical and functional interaction of the HECT ubiquitin-protein ligases E6AP and HERC2 . J Biol Chem . 2011 ; 286 ( 22 ): 19410 - 6 .

Pérez-Villegas EM , Ruiz R , Bachiller S , Ventura F , Armengol JA , Rosa JL . The HERC proteins and the nervous system . Semin Cell Dev Biol . 2022 ; 132 : 5 - 15 .

Sinha Ray S , Dutta D , Dennys C , Powers S , Roussel F , Lisowski P , et al . Mechanisms of IRF2BPL-related disorders and identification of a potential therapeutic strategy . Cell Rep . 2022 ; 41 ( 10 ): 111751 .

Marcogliese PC , Dutta D , Ray SS , Dang NDP , Zuo Z , Wang Y , et al . Loss of IRF2BPL impairs neuronal maintenance through excess Wnt signaling . Sci Adv . 2022 ; 8 ( 3 ): eabl5613 .

Bauersachs D , Bomholtz L , Del Rey Mateos S , Kuhn R , Lisowski P . Novel human neurodevelopmental and neurodegenerative disease associated with IRF2BPL gene variants-mechanisms and therapeutic avenues . Front Neurosci . 2024 ; 18 : 1426177 .

Costa C , Oliver KL , Calvello C , Cameron JM , Imperatore V , Tonelli L , et al . IRF2BPL: a new genotype for progressive myoclonus epilepsies . Epilepsia . 2023 ; 64 ( 8 ): e164 - e9 .

Xing G , Jing H , Zhang L , Cao Y , Li L , Zhao K , et al . A mechanism in agrin signaling revealed by a prevalent Rapsyn mutation in congenital myasthenic syndrome . Elife . 2019 ; 8 .

Zhou J , Chuang Y , Redding-Ochoa J , Zhang R , Platero AJ , Barrett AH , et al . The autophagy adaptor TRIAD3A promotes tau fibrillation by nested phase separation . Nat Cell Biol . 2024 ; 26 ( 8 ): 1274 - 86 .

George AJ , Dong B , Lail H , Gomez M , Hoffiz YC , Ware CB , et al . Erratum: the E3 ubiquitin ligase RNF216/TRIAD3 is a key coordinator of the hypothalamic-pituitary-gonadal axis . iScience . 2022 ; 25 ( 10 ): 105108 .

Nakatochi M , Kushima I , Aleksic B , Kimura H , Kato H , Inada T , et al . Copy number variations in RNF216 and postsynaptic membrane-associated genes are associated with bipolar disorder: a case-control study in the Japanese population . Psychiatry Clin Neurosci . 2025 ; 79 ( 1 ): 12 - 20 .

Santens P , Van Damme T , Steyaert W , Willaert A , Sablonnière B , De Paepe A , et al . RNF216 mutations as a novel cause of autosomal recessive Huntington-like disorder . Neurology . 2015 ; 84 ( 17 ): 1760 - 6 .

Perez-Castro MA , Hernandez-Rasco F , Alonso-Bellido IM , Letran-Sanchez MS , Perez-Villegas EM , Vitalle J , et al . HERC1 E3 ubiquitin ligase is necessary for autophagy processes and for the maintenance and homeostasis of vesicles in motor nerve terminals, but not for proteasomal activity . Int J Mol Sci . 2025 ; 26 ( 2 ): 793 .

Venkateswaran S , Michaud J , Ito Y , Geraghty M , Lewis EC , Ellezam B , et al . IRF2BPL-related disorder, causing neurodevelopmental disorder with regression, abnormal movements, loss of speech and seizures (NEDAMSS) is characterized by pathology consistent with DRPLA . Mov Disord . 2024 ; 39 ( 11 ): 2102 - 9 .

Wang P , Dai X , Jiang W , Li Y , Wei W . RBR E3 ubiquitin ligases in tumorigenesis . Semin Cancer Biol . 2020 ; 67 ( Pt 2 ): 131 - 44 .

Xu C , Feng K , Zhao X , Huang S , Cheng Y , Qian L , et al . Regulation of autophagy by E3 ubiquitin ligase RNF216 through BECN1 ubiquitination . Autophagy . 2014 ; 10 ( 12 ): 2239 - 50 .

Nowak B , Kozlowska E , Pawlik W , Fiszer A . Atrophin-1 function and dysfunction in dentatorubral-pallidoluysian atrophy . Mov Disord . 2023 ; 38 ( 4 ): 526 - 36 .

Beasley SA , Kellum CE , Orlomoski RJ , Idrizi F , Spratt DE . An Angelman syndrome substitution in the HECT E3 ubiquitin ligase C-terminal Lobe of E6AP affects protein stability and activity . PLoS One . 2020 ; 15 ( 7 ): e0235925 .

Miller VM , Nelson RF , Gouvion CM , Williams A , Rodriguez-Lebron E , Harper SQ , et al . CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo . J Neurosci . 2005 ; 25 ( 40 ): 9152 - 61 .

Jana NR , Dikshit P , Goswami A , Kotliarova S , Murata S , Tanaka K , et al . Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes . J Biol Chem . 2005 ; 280 ( 12 ): 11635 - 40 .

Zhang S , Hu ZW , Mao CY , Shi CH , Xu YM . CHIP as a therapeutic target for neurological diseases . Cell Death Dis . 2020 ; 11 ( 9 ): 727 .

Arana AJ , Sanchez L . Knockout, knockdown, and the schrodinger paradox: genetic immunity to phenotypic recapitulation in zebrafish . Genes (Basel) . 2024 ; 15 ( 9 ): 1164 .

Tanji K , Kamitani T , Mori F , Kakita A , Takahashi H , Wakabayashi K . TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson’s disease and dementia with Lewy bodies . Neurobiol Dis . 2010 ; 38 ( 2 ): 210 - 8 .

Deng S , Zhang Z , Liu L , Xu C , Zhang D , Dong L , et al . The E3 ligase c-Cbl modulates microglial phenotypes and contributes to Parkinson’s disease pathology . Cell Death Discov . 2025 ; 11 ( 1 ): 184 .

Dale B , Cheng M , Park KS , Kaniskan H , Xiong Y , Jin J . Advancing targeted protein degradation for cancer therapy . Nat Rev Cancer . 2021 ; 21 ( 10 ): 638 - 54 .

Xiong Y , Zhong Y , Yim H , Yang X , Park KS , Xie L , et al . Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets . J Am Chem Soc . 2022 ; 144 ( 49 ): 22622 - 32 .

Gizynska M , Witkowska J , Karpowicz P , Rostankowski R , Chocron ES , Pickering AM , et al . Proline- and arginine-rich peptides as flexible allosteric modulators of human proteasome activity . J Med Chem . 2019 ; 62 ( 1 ): 359 - 70 .

Shlevkov E , Murugan P , Montagna D , Stefan E , Hadzipasic A , Harvey JS , et al . Discovery of small-molecule positive allosteric modulators of Parkin E3 ligase . iScience . 2022 ; 25 ( 1 ): 103650 .

Yi W , Macdougall EJ , Tang MY , Krahn AI , Gan-Or Z , Trempe JF , et al . The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinson’s disease . Hum Mol Genet . 2019 ; 28 ( 17 ): 2811 - 25 .

Hong WL , Huang H , Zeng X , Duan CY . Targeting mitochondrial quality control: new therapeutic strategies for major diseases . Mil Med Res . 2024 ; 11 ( 1 ): 59 .

Ji CH , Kim HY , Lee MJ , Heo AJ , Park DY , Lim S , et al . The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system . Nat Commun . 2022 ; 13 ( 1 ): 904 .

Zhou Z , Liang J , Cheng B , Li Y , Zhou W , Tian H , et al . Targeted degradation technologies utilizing autophagy . Int J Mol Sci . 2025 ; 26 ( 14 ): 6576 .

Xie X , Yu T , Li X , Zhang N , Foster LJ , Peng C , et al . Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials . Signal Transduct Target Ther . 2023 ; 8 ( 1 ): 335 .

Luo H , Tian Y , Abdullah R , Zhang B , Ma Y , Zhang G . Advancing design strategy of PROTACs for cancer therapy . MedComm (2020) . 2025 ; 6 ( 7 ): e70258 .

Hamilton EP , Jeselsohn RM , Vahdat LT , Hurvitz SA . Proteolysis targeting chimera (PROTAC) estrogen receptor degraders for treatment of estrogen receptor-positive advanced breast cancer . Target Oncol . 2025 ; 20 ( 3 ): 431 - 44 .

Lu M , Liu T , Jiao Q , Ji J , Tao M , Liu Y , et al . Discovery of a Keap1-dependent peptide PROTAC to knockdown tau by ubiquitination-proteasome degradation pathway . Eur J Med Chem . 2018 ; 146 : 251 - 9 .

Li Y , Guo Y , Ma S , Long B , Kong R , Huang X , et al . Prodrug strategy for PROTACs: high efficiency and low toxicity . ACS Omega . 2025 ; 10 ( 23 ): 23926 - 42 .

Ma Z , Zhou J . NDA Submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders . J Med Chem . 2025 ; 68 ( 14 ): 14129 - 36 .

Niessen J , Arendt N , Sjoblom M , Dubbelboer IR , Borchardt T , Koziolek M , et al . A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats . Eur J Pharm Biopharm . 2025 ; 211 : 114719 .

Cotton AD , Nguyen DP , Gramespacher JA , Seiple IB , Wells JA . Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1 . J Am Chem Soc . 2021 ; 143 ( 2 ): 593 - 8 .

Gramespacher JA , Cotton AD , Burroughs PWW , Seiple IB , Wells JA . Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins . ACS Chem Biol . 2022 ; 17 ( 5 ): 1259 - 68 .

Lu X , Jin J , Wu Y , Liu X , Liang X , Lin J , et al . Progress in RAS-targeted therapeutic strategies: from small molecule inhibitors to proteolysis targeting chimeras . Med Res Rev . 2024 ; 44 ( 2 ): 812 - 32 .

Dong Y , Ma T , Xu T , Feng Z , Li Y , Song L , et al . Characteristic roadmap of linker governs the rational design of PROTACs . Acta Pharm Sin B . 2024 ; 14 ( 10 ): 4266 - 95 .

Mi D , Huang A , Song J , Chen Y . A long march for targeted protein degradation in the new era: expanding E3 ligases . Future Med Chem . 2024 ; 16 ( 21 ): 2189 - 91 .

Jang Y , Choi J , Park B , Park JY , Lee JH , Goo J , et al . Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy . Acta Pharm Sin B . 2025 ; 15 ( 9 ): 4886 - 99 .

Chu TT , Gao N , Li QQ , Chen PG , Yang XF , Chen YX , et al . Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation . Cell Chem Biol . 2016 ; 23 ( 4 ): 453 - 61 .

Jiang X , Zhou J , Wang Y , Liu X , Xu K , Xu J , et al . PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases . Eur J Med Chem . 2021 ; 210 : 112949 .

Liu X , Kalogeropulou AF , Domingos S , Makukhin N , Nirujogi RS , Singh F , et al . Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2 . J Am Chem Soc . 2022 ; 144 ( 37 ): 16930 - 52 .

Kargbo RB . PROTAC compounds targeting alpha-synuclein protein for treating neurogenerative disorders: Alzheimer's and Parkinson’s diseases . ACS Med Chem Lett . 2020 ; 11 ( 6 ): 1086 - 7 .

Cao S , Kang S , Mao H , Yao J , Gu L , Zheng N . Defining molecular glues with a dual-nanobody cannabidiol sensor . Nat Commun . 2022 ; 13 ( 1 ): 815 .

Schaefer A , O'carroll D , Tan CL , Hillman D , Sugimori M , Llinas R , et al . Cerebellar neurodegeneration in the absence of microRNAs . J Exp Med . 2007 ; 204 ( 7 ): 1553 - 8 .

Abe M , Bonini NM . MicroRNAs and neurodegeneration: role and impact . Trends Cell Biol . 2013 ; 23 ( 1 ): 30 - 6 .

Wu L , Bai L , Dai W , Wu Y , Xi P , Zhang J , et al . Ginsenoside Rg3: a review of its anticancer mechanisms and potential therapeutic applications . Curr Top Med Chem . 2024 ; 24 ( 10 ): 869 - 84 .

Qi LFR , Qian C , Liu S , Peng C , Zhang M , Yang P , et al . Discovery of a molecular glue that enhances UPRmt to restore proteostasis via TRKA-GRB2-EVI1-CRLS1 axis . bioRxiv . 2021 ; https://doi.org/10.1101/2021.02.17.431525 https://doi.org/10.1101/2021.02.17.431525 .

Subramanian M , Hyeon SJ , Das T , Suh YS , Kim YK , Lee JS , et al . UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation . Nat Commun . 2021 ; 12 ( 1 ): 3291 .

Fang Y , Liao G , Yu B . Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives . Acta Pharm Sin B . 2020 ; 10 ( 7 ): 1253 - 78 .

Haronikova L , Bonczek O , Zatloukalova P , Kokas-Zavadil F , Kucerikova M , Coates PJ , et al . Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them? . Cell Mol Biol Lett . 2021 ; 26 ( 1 ): 53 .

Robbins DW , Noviski MA , Tan YS , Konst ZA , Kelly A , Auger P , et al . Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton's tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies . J Med Chem . 2024 ; 67 ( 4 ): 2321 - 36 .

Tsai JM , Nowak RP , Ebert BL , Fischer ES . Targeted protein degradation: from mechanisms to clinic . Nat Rev Mol Cell Biol . 2024 ; 25 ( 9 ): 740 - 57 .

Liu J , Chen H , Ma L , He Z , Wang D , Liu Y , et al . Light-induced control of protein destruction by opto-PROTAC . Sci Adv . 2020 ; 6 ( 8 ): eaay5154 .

Wang N , Jiang Y , Li M , Wang H , Pan J , Tang Y , et al . Protein kinase STK24 promotes tumor immune evasion via the AKT-PD-L1 axis . Adv Sci (Weinh) . 2024 ; 11 ( 12 ): e2304342 .

Tashima T . Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier . Antibodies . 2023 ; 12 ( 3 ): 43 .

Nguyen TM , Sreekanth V , Deb A , Kokkonda P , Tiwari PK , Donovan KA , et al . Proteolysis-targeting chimeras with reduced off-targets . Nat Chem . 2024 ; 16 ( 2 ): 218 - 28 .

Zeng S , Huang W , Zheng X , Liyan C , Zhang Z , Wang J , et al . Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges . Eur J Med Chem . 2021 ; 210 : 112981 .

Chisholm CG , Bartlett R , Brown ML , Proctor EJ , Farrawell NE , Gorman J , et al . Development of a targeted BioPROTAC degrader selective for misfolded SOD1 . Nat Commun . 2025 ; 16 ( 1 ): 9713 .

Lee C , Lim J . Targeting the mutant androgen receptor with PROTACs in spinal and bulbar muscular atrophy . Neurotherapeutics . 2025 ; 22 ( 6 ): e00771 .

Sangotra A , Lieberman AP . Therapeutic targeting of the polyglutamine androgen receptor in spinal and bulbar muscular atrophy . Expert Opin Ther Targets . 2025 ; 29 ( 1-2 ): 29 - 41 .

Sangotra A , Reddy SL , Kuo CJ , Xiang W , Merry DE , Grunseich C , et al . PROTACs therapeutically target the polyglutamine androgen receptor in spinal and bulbar muscular atrophy models . Neurotherapeutics . 2025 ; 22 ( 6 ): e00732 .

Fischer ES , Böhm K , Lydeard JR , Yang H , Stadler MB , Cavadini S , et al . Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide . Nature . 2014 ; 512 ( 7512 ): 49 - 53 .

Buckley DL , Van Molle I , Gareiss PC , Tae HS , Michel J , Noblin DJ , et al . Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction . J Am Chem Soc . 2012 ; 134 ( 10 ): 4465 - 8 .

Li K , Crews CM . PROTACs: past, present and future . Chem Soc Rev . 2022 ; 51 ( 12 ): 5214 - 36 .

Banik SM , Pedram K , Wisnovsky S , Ahn G , Riley NM , Bertozzi CR . Lysosome-targeting chimaeras for degradation of extracellular proteins . Nature . 2020 ; 584 ( 7820 ): 291 - 7 .

Zhu R , Zhang H , Chen PR . Targeted protein degradation in the transmembrane and extracellular space . Science . 2025 ; 390 ( 6776 ): eadx5094 .

Maneiro MA , Forte N , Shchepinova MM , Kounde CS , Chudasama V , Baker JR , et al . Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4 . ACS Chem Biol . 2020 ; 15 ( 6 ): 1306 - 12 .

He S , Gao F , Ma J , Ma H , Dong G , Sheng C . Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer . Angew Chem Int Ed Engl . 2021 ; 60 ( 43 ): 23299 - 305 .

Verhoef CJA , Crowe C , Nakasone MA , Delacuadra-Basté A , Harzing T , Span NaS , et al . Induced ubiquitination of the partially disordered estrogen receptor alpha protein via a 14-3-3-directed molecular glue-based PROTAC design . bioRxiv . 2025 ; https://doi.org/10.1101/2025.11.17.688825 https://doi.org/10.1101/2025.11.17.688825 .

Visser EJ , Collier MD , Siefert JC , Konstantinidou M , Paul SN , Berkhout JB , et al . Estrogen receptor α/14-3-3 molecular glues as alternative treatment strategy for endocrine resistant breast cancer . bioRxiv . 2024 ; https://doi.org/10.1101/2024.04.25.591105 https://doi.org/10.1101/2024.04.25.591105 .

Wang X , Chen S , Xia X , Du Y , Wei Y , Yang W , et al . Lysosome-targeting protein degradation through endocytosis pathway triggered by polyvalent nano-chimera for AD therapy . Adv Mater . 2025 ; 37 ( 5 ): e2411061 .

Poirson J , Cho H , Dhillon A , Haider S , Imrit AZ , Lam MHY , et al . Proteome-scale discovery of protein degradation and stabilization effectors . Nature . 2024 ; 628 ( 8009 ): 878 - 86 .

Jiang X , Lai Y , Xia W , Yang W , Wang J , Pan J , et al . Self-oxygenating PROTAC microneedle for spatiotemporally-confined protein degradation and enhanced glioblastoma therapy . Adv Mater . 2025 ; 37 ( 13 ): e2411869 .

Xu Q , Hu X , Ullah I , Lin T , Liu Y , Dong H , et al . Biomimetic hybrid PROTAC nanovesicles block multiple DNA repair pathways to overcome temozolomide resistance against orthotopic glioblastoma . Adv Mater . 2025 ; 37 ( 29 ): e2504253 .

Kastl JM , Davies G , Godsman E , Holdgate GA . Small-molecule degraders beyond PROTACs-challenges and opportunities . SLAS Discov . 2021 ; 26 ( 4 ): 524 - 33 .